A pulse rapamycin therapy for infantile spasms and associated cognitive decline. - Wikidata - awgldk - TriplyDB

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

http://www.wikidata.org/entity/Q30501073

about

Identification of new epilepsy treatments: issues in preclinical methodology Basic mechanisms of catastrophic epilepsy -- overview from animal models Harnessing the power of metabolism for seizure prevention: focus on dietary treatments Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studies Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex Efficacy and tolerability of the galanin analog NAX 5055 in the multiple-hit rat model of symptomatic infantile spasms.CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms.The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile s The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway.Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction.The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice.Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies.Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage.mTOR signaling in epilepsy: insights from malformations of cortical development Epilepsy as a neurodevelopmental disorder.Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy.Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats.Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats.Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures.Issues for new antiepilepsy drug development.Is mTOR inhibition a systemic treatment for tuberous sclerosis?Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials.Mammalian target of rapamycin (mTOR) pathways in neurological diseases.Epilepsy Mechanisms in Neurocutaneous Disorders: Tuberous Sclerosis Complex, Neurofibromatosis Type 1, and Sturge-Weber Syndrome.Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).Vigabatrin monotherapy for infantile spasms.Novel animal models of pediatric epilepsy.Latest American and European updates on infantile spasms.Adrenocorticotropic hormone for the treatment of West Syndrome in children.mTOR inhibitors as a new therapeutic option for epilepsy.Recent advances in the pharmacotherapy of infantile spasms.Pathophysiology of epileptic encephalopathies.Pathogenetic mechanisms of focal cortical dysplasia.Autophagy and amino acid metabolism in the brain: implications for epilepsy.The role of autophagy in epileptogenesis and in epilepsy-induced neuronal alterations.mTOR inhibition in epilepsy: rationale and clinical perspectives.

P2860

Q24289140-9E59C12B-145D-479B-A58A-4B285AE6FD87 Q26864346-D70C24EC-4CE6-4DAB-A977-4E1C42890358 Q26991869-2DE333BF-FAA9-4D95-B6C4-2A9D4E951398 Q27024547-ACD39670-EDCD-4AE3-B63F-23EEC35CC4B8 Q27308052-049BC61D-F130-4745-B0B1-3341DDDC3C3B Q27319659-88837FFF-2182-45BE-BA7A-79B384291695 Q28486250-DEE5AA10-5BB8-403E-B0E2-FF4AEC96E747 Q30560643-038C9C1A-26C5-4DA0-AB38-9B486EBB8740 Q30584190-98EB64F6-70BA-4918-9D29-1953343555B2 Q34240602-40C1825A-FF14-490C-B110-12C69FF3D01D Q34261603-5C2FC413-A373-45AD-949B-BA25A91FC273 Q34339959-42E5B8C1-F790-4D81-AA30-5D05FEC552CB Q34416405-8C6619FD-62B5-4744-BB9A-69B284176DE2 Q34503246-11C5A18E-3F1F-4FA3-84C0-B8AF25E098A3 Q34639033-CEA80D5F-1112-4B3B-A6AF-82468E3E53B1 Q35245211-2868C010-78AC-4C28-AFEE-8BD4E1AC67B8 Q35838099-E5F72D7F-1E85-4BF7-A4C3-6434F11A3922 Q36019947-A506616E-CB83-4F19-A59D-FC8072C6CF15 Q36110085-DBF166F5-D7B8-4710-BE5D-6884C285DB43 Q36395227-48AD8A36-8DA4-4788-A3F7-D136418A2D1B Q36410001-E7480BED-9C28-4F87-B032-008707287716 Q36411217-5C77AEC9-C19E-4568-85C1-618EE403390D Q37164052-8F7A9CF6-83D3-48A7-B938-0FD76DDAE839 Q37359517-F703DFFF-EDF9-4783-B963-3C84133BAFD7 Q37419781-597FF1A9-9542-498A-A3AC-6D8B98814F11 Q37419785-1C0ED670-8774-4904-947A-96F98147CF5E Q37432305-9C0CD5D2-79F2-4E66-A164-40A5C19907FE Q37707250-6F9AD097-8E33-44AB-95C0-FD6DAA122DA5 Q37717421-29B717E0-2AF1-4E57-95D1-7BE2AB75CCA4 Q37987986-045F1B8E-60F3-4FF8-A237-F663CFFD98AD Q37998957-B1E1D47C-D9C9-4B3A-ACE0-EA8DF3A31607 Q38076086-048F25F1-723C-45C3-A55B-EBC5881AF4B5 Q38100763-5D7A5076-4BDC-4278-8206-99D164918A62 Q38112211-B3EFD84B-A3BD-430C-9C70-5024DB3C2C9D Q38185985-E56FEEB3-590D-4AF6-A332-69DAEE8D320A Q38191243-170452BB-901D-4C88-8E37-3E3B498CBE55 Q38214869-A900FA9A-634A-48B9-83FD-1B02F1112659 Q38242039-1252C1D9-BD05-414A-8320-6F65CDF9447F Q38248845-0C8394ED-E8C1-4F66-96FC-D3819EEEB8D4 Q38336887-6D711F00-AB00-43B5-8F08-D96586BA2EC3

P2860

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

http://www.wikidata.org/entity/Q30501073

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

@ast

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

@en

type

label

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

@ast

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

@en

prefLabel

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

@ast

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

@en

P1433

Q30501073-D4DAF38E-0FB9-4A14-B1E9-4DCDCD0B1278

P1476

Q30501073-10D2F5D3-E7DA-4296-978E-399B20F806D7

P2093

Q30501073-050D6EAF-C1F6-47EC-BDFB-DA9795BBD664

Q30501073-1060AB69-23EE-4570-80CB-B9D31DB1489F

Q30501073-185A5F88-E041-4342-9531-F044FAE395C5

Q30501073-6700172A-BDE4-4D39-B5EE-6941CE563FFF

Q30501073-BB220ADE-DCE2-4C0A-A141-A3C45A2A372C

P2860

Q30501073-0227834E-35AF-4922-B813-1909E87C8E80

Q30501073-05BB6EA1-1FBA-4071-A649-8F7AD5F42537

Q30501073-0799B149-2C1A-42E5-AC4C-F4D9A567D4F6

Q30501073-08B3CD2E-0DCB-4A29-BE2D-F7DFB4745D3D

Q30501073-1D78687D-A156-46FB-A05C-2B33A5892A51

Q30501073-20F71E85-76D9-4288-888C-11DD24032DFE

Q30501073-27CC240E-6A6A-45B9-B35A-67D337102A59

Q30501073-2E42027C-7903-4166-8687-60FC0EEE0147

Q30501073-30EE18BD-F5C3-4AF1-A2C3-C4FB8023C0C6

Q30501073-32E4D2C5-BC4F-4EC3-AA6E-8BC29F3FB4C8

P304

Q30501073-8B968467-F528-4719-BD8B-80E8FF923052

P31

Q30501073-0C5A6D74-941D-4325-B201-AC919AEFEDAB

P356

Q30501073-B32644C6-A85E-4A13-AE6D-61F48147CD30

P433

Q30501073-A84E47ED-8497-45CD-8A13-F40745A10699

P478

Q30501073-A7845A6A-6781-440D-AB6C-686AB71C4EF7

P577

Q30501073-3309A008-2328-4B92-8369-C80DA31718CD

P5875

Q30501073-EECAA5D8-99A4-4B1A-8207-728EC619C8CD

P698

Q30501073-92F1D036-7257-4B92-829C-A4DFB0801F9C

P932

Q30501073-F535F80C-F6BD-40EE-A81B-9502209CC91A

P356

J.NBD.2011.03.021

P1433

Neurobiology of Disease

P1476

A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

@en

P2093

Antonietta Coppola

http://www.w3.org/2001/XMLSchema#string

Aristea S Galanopoulou

http://www.w3.org/2001/XMLSchema#string

Emmanuel Raffo

http://www.w3.org/2001/XMLSchema#string

Stephen W Briggs

http://www.w3.org/2001/XMLSchema#string

Tomonori Ono

http://www.w3.org/2001/XMLSchema#string

P2860

The tuberous sclerosis complex

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009

The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial

The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

A model of symptomatic infantile spasms syndrome

Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy.

Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice

P304

322-329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NBD.2011.03.021

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51062441

http://www.w3.org/2001/XMLSchema#string

P698

21504792

http://www.w3.org/2001/XMLSchema#string

P932

3114281

http://www.w3.org/2001/XMLSchema#string